Cipla has expressed reservations over certain key components of licensing terms with the Medicines Patent Pool, which recently signed its first licence agreement with Gilead Sciences for five products for the treatment of HIV and hepatitis B.
In response to a specific query from Scrip following the Indian firm's annual general meeting in Mumbai, Cipla's chairman, Dr...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?